Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hormel Foods Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while Hormel Foods Corp trades at $24.45 (market cap $13.61B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 4.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HRL | |
|---|---|---|
Market Cap | $39.89B | $13.61B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $30.51 |
52-Week Low | $278.09 | $19.74 |
Enterprise Value | $38.15B | $15.61B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Hormel Foods (HRL) trades at $24.735, up 1.66% today, with a bearish technical signal but consistent earnings beats in recent quarters. The company maintains a 60-year dividend growth streak, paying $0.29 quarterly, while navigating margin pressures with a 3.82% net income margin. Recent news highlights strategic moves like the Ceratti Brazil sale to sharpen growth focus, though revenue trends remain flat near $12.1B.
Outlook is mixed: valuation appears reasonable (P/E 29.09, P/S 1.11) with analyst consensus at $26.00, but risks include volatile cash flows and competitive pressures. The stock offers income stability via dividends, yet investors face headwinds from inflation and sluggish profit growth, requiring patience for a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
